> Detailanzeige

Peluso, Michael J; Lu, Scott; Tang, Alex F; Durstenfeld, Matthew S; Ho, Hsi-en; Goldberg, Sarah A; Forman, Carrie A; Munter, Sadie E; Hoh, Rebecca; Tai, Viva; Chenna, Ahmed; Yee, Brandon C; Winslow, John W; Petropoulos, Christos J; Greenhouse, Bryan; Hunt, Peter W; Hsue, Priscilla Y; Martin, Jeffrey N; Daniel Kelly, J; Glidden, David V; Deeks, Steven G; Henrich, Timothy J

Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
  • Beteiligte: Peluso, Michael J; Lu, Scott; Tang, Alex F; Durstenfeld, Matthew S; Ho, Hsi-en; Goldberg, Sarah A; Forman, Carrie A; Munter, Sadie E; Hoh, Rebecca; Tai, Viva; Chenna, Ahmed; Yee, Brandon C; Winslow, John W; Petropoulos, Christos J; Greenhouse, Bryan; Hunt, Peter W; Hsue, Priscilla Y; Martin, Jeffrey N; Daniel Kelly, J; Glidden, David V; Deeks, Steven G; Henrich, Timothy J
  • Erschienen: Oxford University Press (OUP), 2021
  • Erschienen in: The Journal of Infectious Diseases
  • Sprache: Englisch
  • DOI: 10.1093/infdis/jiab490
  • ISSN: 0022-1899; 1537-6613
  • Schlagwörter: Infectious Diseases ; Immunology and Allergy
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>The biological processes associated with postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) are unknown.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We measured soluble markers of inflammation in a SARS-CoV-2 recovery cohort at early (&amp;lt;90 days) and late (&amp;gt;90 days) timepoints. We defined PASC as the presence of 1 or more coronavirus disease 2019 (COVID-19)–attributed symptoms beyond 90 days. We compared fold-changes in marker values between those with and without PASC using mixed-effects models with terms for PASC and early and late recovery time periods.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>During early recovery, those who went on to develop PASC generally had higher levels of cytokine biomarkers including tumor necrosis factor–α (1.14-fold higher mean ratio [95% confidence interval {CI}, 1.01–1.28]; P = .028) and interferon-γ–induced protein 10 (1.28-fold higher mean ratio [95% CI, 1.01–1.62]; P = .038). Among those with PASC, there was a trend toward higher interleukin 6 levels during early recovery (1.29-fold higher mean ratio [95% CI, .98–1.70]; P = .07), which became more pronounced in late recovery (1.44-fold higher mean ratio [95% CI, 1.11–1.86]; P &amp;lt; .001). These differences were more pronounced among those with a greater number of PASC symptoms.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Persistent immune activation may be associated with ongoing symptoms following COVID-19. Further characterization of these processes might identify therapeutic targets for those experiencing PASC.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang